GMDAQ vs. WINT, ELOX, ALBT, FNCH, KRBP, TCBP, SCNI, SQZ, TCON, and FRTX
Should you be buying Gamida Cell stock or one of its competitors? The main competitors of Gamida Cell include Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), TC Biopharm (TCBP), Scinai Immunotherapeutics (SCNI), SQZ Biotechnologies (SQZ), TRACON Pharmaceuticals (TCON), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.
Windtree Therapeutics (NASDAQ:WINT) and Gamida Cell (NASDAQ:GMDAQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
Windtree Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
Windtree Therapeutics' return on equity of 0.00% beat Gamida Cell's return on equity.
Windtree Therapeutics received 3 more outperform votes than Gamida Cell when rated by MarketBeat users.
In the previous week, Windtree Therapeutics had 3 more articles in the media than Gamida Cell. MarketBeat recorded 4 mentions for Windtree Therapeutics and 1 mentions for Gamida Cell. Windtree Therapeutics' average media sentiment score of 1.38 beat Gamida Cell's score of 0.37 indicating that Gamida Cell is being referred to more favorably in the news media.
Windtree Therapeutics has higher earnings, but lower revenue than Gamida Cell. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of Gamida Cell shares are owned by institutional investors. 0.5% of Windtree Therapeutics shares are owned by insiders. Comparatively, 6.7% of Gamida Cell shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Gamida Cell beats Windtree Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Gamida Cell News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMDAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMDAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GMDAQ vs. The Competition
Gamida Cell Competitors List
Related Companies and Tools
